Resorcinol was anticipated to become the first substance to be concluded as a substance of very high concern (SVHC) based on its effects on the thyroid functioning. However, the discussion within the REACH Committee caused a split among EU members as reported in our previous newsletter.
Shortly after the announcement of a positive outcome had been made, the EU Commission had to reverse the conclusion and change it into a “no opinion” verdict. This was the consequence of an error in the interpretation of the outcome of the voting among the EU member states.
The Commission still wants to pursue a positive identification of resorcinol as an SVHC substance, but so far it is undecided in what way.
For more information on endocrine disruptors, please contact:
Brian Svend Nielsen
bsn@dhigroup.com
Tel +45 4516 9140
LinkedIn